web analytics

Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

Stockholm – September 11, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that clinical trial data were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in Houston, TX, USA. In an oral presentation, data from the pivotal Phase 2 HORIZON clinical trial were presented as part of the meeting’s multiple myeloma session. Additionally, two posters focused on the ANCHOR and HORIZON clinical trials evaluating melflufen in RRMM were displayed at the meeting. The data presented are encouraging and show continued momentum for Oncopeptides’ melflufen.
In the

Source: Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.